Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen density

M C Beduschi1, J E Oesterling

  • 1Michigan Prostate Institute, Ann Arbor, USA.

The Urologic Clinics of North America
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

The Journal of urology·1999
Same author

Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

The Journal of urology·1999
Same author

Antifibrinolytic additives to fibrin glue for laparoscopic wound closure in urinary tract.

Journal of endourology·1999
Same author

Have complication rates decreased after treatment for localized prostate cancer?

The Journal of urology·1999
Same author

Pneumoperitoneum does not potentiate the nephrotoxicity of aminoglycosides in rats.

Urology·1999
Same author

Reference ranges for serum prostate-specific antigen in black and white men without cancer.

Urology·1998

Prostate-Specific Antigen (PSA) is a key tumor marker for prostate cancer, but struggles to differentiate BPH from cancer. Prostate-Specific Antigen Density (PSAD) improves diagnostic accuracy, aiding in early detection and reducing unnecessary biopsies.

Area of Science:

  • Urologic Oncology
  • Biomarker Development
  • Cancer Diagnostics

Background:

  • Prostate-Specific Antigen (PSA) has been a cornerstone tumor marker in urologic oncology for nearly two decades.
  • While crucial for monitoring prostate cancer therapy and mass screening, PSA exhibits limitations in distinguishing benign prostatic hyperplasia (BPH) from prostate cancer.
  • Enhancing PSA's sensitivity, specificity, and predictive value necessitates addressing confounding factors.

Purpose of the Study:

  • To evaluate the utility of Prostate-Specific Antigen Density (PSAD) as a refined screening parameter.
  • To assess PSAD's effectiveness in differentiating BPH from prostate cancer in patients with intermediate PSA levels.
  • To explore how PSAD can improve the cost-effectiveness and accuracy of prostate cancer screening.

Main Methods:

Related Experiment Videos

  • Development of the PSAD concept based on the relationship between PSA, prostate volume, and serum PSA levels.
  • Application of PSAD in diverse patient cohorts for diagnostic and staging purposes.
  • Analysis of accumulated data to demonstrate PSAD's clinical utility and cost-effectiveness.

Main Results:

  • PSAD has demonstrated significant usefulness as a second-line screening parameter.
  • It effectively helps distinguish BPH from prostate cancer in cases with intermediate PSA values.
  • The use of PSAD has the potential to reduce the number of unnecessary prostate biopsies.

Conclusions:

  • PSAD offers a valuable improvement over PSA alone for prostate cancer screening and diagnosis.
  • While not a definitive standalone solution, PSAD enhances diagnostic capabilities, particularly in equivocal cases.
  • Integrating PSAD with other diagnostic methods provides a comprehensive approach to assessing at-risk populations and promoting well-being.